Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial-Reference-Cited by-同舟云学术

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

Published:2012-02 Issue:9816 Volume:379 Page:633-640
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Baselga José,Bradbury Ian,Eidtmann Holger,Di Cosimo Serena,de Azambuja Evandro,Aura Claudia,Gómez Henry,Dinh Phuong,Fauria Karine,Van Dooren Veerle,Aktan Gursel,Goldhirsch Aron,Chang Tsai-Wang,Horváth Zsolt,Coccia-Portugal Maria,Domont Julien,Tseng Ling-Min,Kunz Georg,Sohn Joo Hyuk,Semiglazov Vladimir,Lerzo Guillermo,Palacova Marketa,Probachai Volodymyr,Pusztai Lajos,Untch Michael,Gelber Richard D,Piccart-Gebhart Martine

Publisher

Elsevier BV

Subject

General Medicine

Reference30 articles.

1. ERBB receptors and cancer: the complexity of targeted inhibitors;Hynes;Nat Rev Cancer,2005

2. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2;Slamon;N Engl J Med,2001

3. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer;Romond;N Engl J Med,2005

4. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial;Smith;Lancet,2007

5. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer;Joensuu;N Engl J Med,2006

Cited by 1127 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Additional statin treatment enhances the efficacy of HER2 blockade and improves prognosis in Rac1-high/HER2-positive breast cancer;Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease;2024-12

2. Dual HER2 inhibition: mechanisms of synergy, patient selection, and resistance;Nature Reviews Clinical Oncology;2024-09-13

3. Unveiling Neoadjuvant Therapy: Insights and Outlooks for HER2-Positive Early Breast Cancer;Current Treatment Options in Oncology;2024-08-17

4. Analysis of Factors Associated With Pathological Complete Response in Patients With HER2-Positive Breast Cancer Receiving Neoadjuvant Chemotherapy;Clinical Breast Cancer;2024-08

5. Cost-utility and budget impact analysis of neoadjuvant dual HER2 targeted therapy for HER2-positive breast cancer in Sri Lanka;Scientific Reports;2024-07-20